Mao Qing

Dr. Mao Qing


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Cancer Letters
Verified
Journal Article
Closed access
Tao JiangTao Jiang
Tao Jiang
DNDo-Hyun Nam
Do-Hyun Nam
ZRZvi Ram
Zvi Ram
WPWai-Sang Poon
Wai-Sang Poon
JWJiguang Wang
Jiguang Wang
QWQixue Wang
Qixue Wang

1 June 2016 in Cancer Letters
Verified
Journal Article
Open access
Tao JiangTao Jiang
Tao Jiang
YMYing Mao
Ying Mao
WMWenbin Ma
Wenbin Ma
MQMao Qing
Mao Qing
YYYongping You
Yongping You
QWQixue Wang
Qixue Wang
The Chinese Glioma Cooperative Group (CGCG) Guideline Panel for adult diffuse gliomas provided recommendations for diagnostic and therapeutic procedures. The Panel covered all fields of expertise in neuro-oncology, i.e. neurosurgeons, neurologists, neuropathologists, neuroradiologists, radiation and medical oncologists and clinical trial experts. The task made clearer and more transparent choices about outcomes considered most relevant through searching the references considered most relevant and evaluating their value. The scientific evidence of papers collected from the literature was evaluated and graded based on the Oxford Centre for Evidence-based Medicine Levels of Evidence and recommendations were given accordingly. The recommendations will provide a framework and assurance for the strategy of diagnostic and therapeutic measures to reduce complications from unnecessary treatment and cost. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China.

23 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YRYanming Ren
Yanming Ren
ZHZongyao Huang
Zongyao Huang
LZLingling Zhou
Lingling Zhou
PXPeng Xiao
Peng Xiao
JSJunwei Song
Junwei Song
YWYuan Wang
Yuan Wang
Diffuse midline glioma-H3K27M mutant (DMG) and glioblastoma (GBM) are the most lethal brain tumors that primarily occur in pediatric and adult patients, respectively. Both tumors exhibit significant heterogeneity, shaped by distinct genetic/epigenetic drivers, transcriptional programs including RNA splicing, and microenvironmental cues in glioma niches. However, the spatial organization of cellular states and niche-specific regulatory programs remain to be investigated. Here, we perform a spatial profiling of DMG and GBM combining short- and long-read spatial transcriptomics, and single-cell transcriptomic datasets. We identify clinically relevant transcriptional programs, RNA isoform diversity, and multi-cellular ecosystems across different glioma niches. We find that while the tumor core enriches for oligodendrocyte precursor-like cells, radial glial stem-like (RG-like) cells are enriched in the neuron-rich invasive niche in both DMG and GBM. Further, we identify niche-specific regulatory programs for RG-like cells, and functionally confirm that FAM20C mediates invasive growth of RG-like cells in a neuron-rich microenvironment in a human neural stem cell derived orthotopic DMG model. Together, our results provide a blueprint for understanding the spatial architecture and niche-specific vulnerabilities of DMG and GBM.

13 April 2022 in American Journal of Surgical Pathology
Verified
Journal Article
Open access
LZLinmao Zheng
Linmao Zheng
JGJing Gong
Jing Gong
TYTianping Yu
Tianping Yu
YZYan Zou
Yan Zou
MZMengni Zhang
Mengni Zhang
NCNi Chen
Ni Chen
Diffuse midline glioma, H3 K27M-mutant (H3 K27M-mt DMG), is a rare and highly aggressive tumor that is more common in children than in adults. Few studies have compared the differences between pediatric and adult patients with this rare tumor. We here report our retrospective study of 94 adult and 70 pediatric cases of diffuse midline glioma. Surgical tumor samples were analyzed by routine histopathology and immunohistochemistry for H3 K27M, IDH1 R132H, ATRX, p53, OLIG2, glial fibrillary acidic protein, and Ki-67; Sanger sequencing for hot mutation spots in genes including H3F3A, HIST1H3B, IDH1, IDH2, TERT, and BRAF; and methylation-specific polymerase chain reaction for O 6 -methylguanine DNA methyltransferase promoter methylation. The most frequent anatomic locations in adult and pediatric patients were the thalamus and brainstem, respectively. Molecular profiling revealed higher frequencies of ATRX loss and H3.3 mutation in adult than in pediatric H3 K27M-mt DMGs. TERT promoter mutations and O 6 -methylguanine DNA methyltransferase promoter methylation were not detected in pediatric patients but were present in a few adult patients. During the follow-up period, 93/122 patients (70.1%) died from the disease, with a median survival time of 10.5 months (range: 1 to 104 mo). Kaplan-Meier analyses demonstrated that the prognosis was better for adult patients than the pediatric cohort (P=0.0003). Multivariate analyses indicated that patient age, primary tumor size, status of ATRX expression, and Ki-67 index were independent prognosticators. The present study showed that there were differences between adult and pediatric H3 K27M-mt DMGs in terms of the anatomic location of tumor, molecular changes, and prognosis.

15 January 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
YYYang Yuan
Yang Yuan
LJLi Jiaoming
Li Jiaoming
WXWang Xiang
Wang Xiang
LYLiu Yanhui
Liu Yanhui
SJShu Jiang
Shu Jiang
MQMao Qing
Mao Qing

1 November 2014 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
YYYang Yuan
Yang Yuan
WXWang Xiang
Wang Xiang
MQMao Qing
Mao Qing
LYLiu Yanhui
Liu Yanhui
LJLuo Jiewen
Luo Jiewen
MYMao Yunhe
Mao Yunhe